Skip to main content
. 2020 Feb 11;4(3):530–538. doi: 10.1182/bloodadvances.2019000268

Table 5.

Overall responses with ponatinib

Phase of CML CCyR, n (%) MMR, n (%) MR 4.0, n (%) MR 4.5, n (%)
CP (n = 51) 32/46 (69.6) 27/46 (58.7) 19/46 (41.3) 17/46 (37.0)
AP (n = 9) 3/8 (37.5) 0/8 (0.0) 0/8 (0.0) 0/8 (0.0)
BP (n = 18) 11/16 (68.8) 10/16 (62.5) 7/16 (43.8) 7/16 (43.8)

In CP, the response was unknown in 5 patients; in AP, in 1 patient; and in BP, in 2 patients.